Clinical studies consistently show substantial weight loss outcomes in patients using GLP-1 medications, often accompanied by improvements in blood sugar control, cholesterol levels, and decreased cardiovascular risks
Gut issues are especially common too (present in approximately 64% of cases), and many people on semaglutide experience some combination of constipation (24%), diarrhoea (30%), vomiting (25%), flatulence, fatigue, and abdominal pain
Some people might experience them for a few days, while others might deal with them for a few weeks
A real San Francisco office, not a post-office box
This genetic roadmap helps PlexusDx clinicians determine whether semaglutide injection, tirzepatide injection, oral formulations, the Microdose GLP-1 Protocol ($129/mo), or GLP-Squared combinations are most appropriate for your weight loss goals